Business Development Manager - Antibody Licensing

  • Salary: CHF70000 - CHF75000 per annum
  • REF Number: v-185190
  • Consultant: Robert Angrave
  • Contact: 01246 457716
  • Date Published: 30.04.2026
  • Industry: Biotech
  • Location: Remote work, Switzerland
  • Functional Expertise: Clinical Operations/Development, Board & Leadership

About The Job

Job Title: Business Development Manager – Antibody Licensing

Location: Switzerland - Remote

Company: US-based Biotech (via CK QLS)

CK QLS is partnering with a fast-growing, US-headquartered biotech at the forefront of antibody discovery and development. With cutting-edge platforms and a strong global footprint, the business is advancing a diverse pipeline across immuno-oncology, autoimmune and inflammatory diseases, neurology, and metabolic disorders.

They are now looking for a scientifically strong individual to transition into a Business Development and Lirole focused on the Swiss market, supporting antibody licensing and strategic partnerships. This role offers a clear entry point into BD&L, working closely with global teams to assess opportunities, support deal activity, and help shape collaborations—ideal for someone with an antibody discovery background and a strong interest in moving into a commercial, partner-facing position.

The Role

As a Business Development Manager, you will support and progressively take ownership of identifying, evaluating, and executing strategic partnering opportunities across Switzerland. You’ll gain exposure to the full deal lifecycle while working cross-functionally with global stakeholders.

Job Responsibilities:

  • Establish external business opportunities for out-licensing, co-development, and other structured transactions.
  • Lead the development and presentation of business cases of prioritized external opportunities with recommendations to management team with robust analyses, key assumptions, and risks, as well as internal and external input where necessary.
  • Initiate, lead and present external opportunities with limited supervision.
  • Lead driving cross-functional due diligence and alliance management, coordinate with R&D, CMC, Clinical, Regulatory, Operations, and Finance and executive reporting, in some instances be the main BD contact person.
  • Follow BD operations and transactions including proposals and TS developments, negotiations, deal closure and alliance management.
  • Contribute to the definition and revision of business development &

    licensing strategy that is in line with overall corporate and portfolio strategies.

  • Represent Biocytogen at industry, investor and partnering conferences, develop and maintain relationships with a wide range of pharmaceutical/biotechnology industry participants.
Requirements

  • Ph.D. in pharmacology, immunology, cancer biology, or a related biomedical science field
  • Strong background in antibody drug discovery, with a deep understanding of target validation and hit-to-lead optimization
  • Proven ability to interpret complex biological data (affinity, specificity, and in vivo efficacy) and translate it into a compelling therapeutic and licensing narrative
  • Familiarity with current antibody modalities, including monoclonal antibodies (mAbs), bispecific antibodies, and ADCs
  • Strong strategic thinking skills to align internal scientific platform capabilities with pharmaceutical partner pipeline gaps
  • Mandarin and English bilingual, to effectively bridge global R&D and business communications
Why Apply?

  • Join a high-growth US biotech expanding its presence across the UK and Europe
  • Ideal opportunity for scientists looking to move into business development
  • Gain exposure to international deal-making and strategic partnerships
  • Work closely with global teams in a highly visible role
  • Flexible UK-based working model
Apply

It is essential that applicants hold entitlement to work Switzerland. Please quote job reference 185 124 in all correspondence.

Apply for this job

We'll store this in session so if you're applying for multiple jobs today so you can use this as a base.